Macupatide
LY3532226 · Eli Lilly
A long-acting GIP receptor agonist studied alone and with eloralintide.
Results availability
No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.
Mechanism at a glance
Obesity stage by formulation
Latest: Lilly lists Phase 2 weight-management studies in adults with and without type 2 diabetes; the no-diabetes study is Phase 2b.
Next: Results and Lilly’s next-step development plans.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies1 record
NCT07589608 · obesity without type 2 diabetes
Weight management without type 2 diabetesMaster-protocol study testing macupatide and eloralintide alone or in combination in adults with obesity or overweight without type 2 diabetes.
Related conditions and outcomes
Phase 2 studies1 record
NCT07215559 · obesity with type 2 diabetes
Glycemic control in type 2 diabetesStudy of macupatide and eloralintide alone or in combination in adults with obesity or overweight and type 2 diabetes.
